MCID: GST040
MIFTS: 52

Gastric Adenocarcinoma malady

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Gastric Adenocarcinoma

About this section

Aliases & Descriptions for Gastric Adenocarcinoma:

Name: Gastric Adenocarcinoma 11 13 68
Adenocarcinoma of Stomach 11
 
Stomach Adenocarcinoma 11
Adenocarcinoma Gastric 50

Classifications:



External Ids:

Disease Ontology11 DOID:3717
SNOMED-CT62 408647009
NCIt45 C4004

Summaries for Gastric Adenocarcinoma

About this section
Disease Ontology:11 A stomach carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary: Gastric Adenocarcinoma, also known as adenocarcinoma of stomach, is related to gastric adenocarcinoma and proximal polyposis of the stomach and gastric cardia adenocarcinoma, and has symptoms including dyspepsia An important gene associated with Gastric Adenocarcinoma is CDH1 (Cadherin 1), and among its related pathways are RHO GTPases activate IQGAPs and Secretion of Hydrochloric Acid in Parietal Cells. Affiliated tissues include lymph node, breast and colon, and related mouse phenotypes are integument and endocrine/exocrine gland.

Related Diseases for Gastric Adenocarcinoma

About this section

Diseases related to Gastric Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 238)
idRelated DiseaseScoreTop Affiliating Genes
1gastric adenocarcinoma and proximal polyposis of the stomach11.9
2gastric cardia adenocarcinoma11.3
3gastric cancer risk after h. pylori infection11.1
4adenocarcinoma11.0
5krukenberg carcinoma10.9
6gastric papillary adenocarcinoma10.9
7gastric tubular adenocarcinoma10.9
8mucinous stomach adenocarcinoma10.8
9gastric signet ring cell adenocarcinoma10.8
10substance abuse10.4CDH1, CTNNB1, ERBB2
11reactive arthritis10.4CTNNB1, ERBB2, PTGS2
12nemaline myopathy 8, autosomal recessive10.3CDH1, CTNNB1, ERBB2
13basaloid squamous cell carcinoma10.3CDH1, CEACAM5, ERBB2
14adult myxoid chondrosarcoma10.3CTNNB1, KRT20
15autoimmune pancreatitis10.3CHGA, GAST
16bone giant cell tumor10.3ERBB2, MYC
17acquired hemangioma10.3CDX2, ERBB2, PTGS2
18vagneur triolle ripert syndrome10.3CEACAM5, CHGA
19pulmonary artery choriocarcinoma10.3CEACAM5, ERBB2
20macrocytic anemia10.3CEACAM5, CTNNB1, PTGS2
21gastrointestinal system cancer10.3CDH1, CEACAM5, ERBB2
22vacterl association with hydrocephaly, x-linked10.3AFP, CEACAM5
23ehlers-danlos syndrome, type viic10.3CDH1, CTNNB1, MYC
24ovarian mucinous neoplasm10.3CDX2, GAST, PTGS2
25spastic diplegia infantile type10.3CDX2, CTNNB1, ERBB2
26vulvar keratoacanthoma-like carcinoma10.3CEACAM5, CHGA
27vulva squamous cell carcinoma10.3CEACAM5, ERBB2, KRT20
28thymoma10.3CDX2, CEACAM5, GAST
29neuroendocrine tumor10.3CDX2, KRT20, PTGS2
30dental caries10.3CDH1, CEACAM5, ERBB2
31rete testis adenoma10.3AFP, CEACAM5
32nasal cavity disease10.3CDH1, CEACAM5, ERBB2
33sarcomatoid basal cell carcinoma10.3CDH1, CEACAM5, KRT20
34progesterone-receptor positive breast cancer10.3CDH1, ERBB2, PTGS2
35uterine corpus endometrial stromal sarcoma10.3CEACAM5, KRT20, MLH1
36lattice corneal dystrophy10.3ERBB2, MLH1, PTGS2
37breast cystic hypersecretory carcinoma10.3GAST, PTGS2, S100A8
38glossopharyngeal motor neuropathy10.3CDH1, ERBB2
39prostatic adenoma10.3CTNNB1, ERBB2, MLH1
40vipoma10.3AFP, CHGA
41myotonic disease10.3CDH1, CEACAM5, KRT20
42hyperornithinemia-hyperammonemia-homocitrullinemia syndrome10.3CDX2, GAST, PTGS2
43secondary syphilis10.3CHGA, GAST
44apocrine adenocarcinoma10.3CDX2, CEACAM5, KRT20
45congenital symblepharon10.3CTNNB1, MLH1, PTGS2
46bladder carcinoma in situ10.3AFP, CEACAM5
47brain edema10.3CHGA, GAST
48dysembryoplastic neuroepithelial tumor10.3CDH1, ERBB2, KRT20, PTGS2
49neuroretinitis10.3CDX2, KRT20, MLH1
50papillary adenofibroma10.3CDX2, CEACAM5, KRT20

Graphical network of the top 20 diseases related to Gastric Adenocarcinoma:



Diseases related to gastric adenocarcinoma

Symptoms & Phenotypes for Gastric Adenocarcinoma

About this section

UMLS symptoms related to Gastric Adenocarcinoma:


dyspepsia

MGI Mouse Phenotypes related to Gastric Adenocarcinoma according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00107719.5CCKBR, CDH1, CTNNB1, CTSE, ERBB2, FHIT
2MP:00053799.3AFP, CCKBR, CDH1, CDX2, CHGA, CTNNB1
3MP:00053819.2CCKBR, CDH1, CDX2, CTNNB1, ERBB2, FHIT
4MP:00020069.2AFP, CDH1, CDX2, CTNNB1, ERBB2, FHIT
5MP:00107688.6AFP, CDH1, CDX2, CHGA, CLDN4, CTNNB1
6MP:00053898.4AFP, CDH1, CDX2, CHGA, CTNNB1, CTSE
7MP:00053768.2AFP, CCKBR, CDH1, CDX2, CHGA, CLDN4

Drugs & Therapeutics for Gastric Adenocarcinoma

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)16 Company Approval Date
1
Taxotere16 44 DOCETAXEL Rhone Poulenc Rorer May 1996
FDA Label: Taxotere
Disease/s that Drug Treats:breast cancer
Indications and Usage:16 TAXOTERE is a microtubule inhibitor indicated for: Breast Cancer (BC): single agent for locally advanced or metastatic BCafter chemotherapy failure; and with doxorubicin andcyclophosphamide as adjuvant treatment of operable node-positive BC(1.1) Non-Small Cell Lung Cancer (NSCLC): single agent for locallyadvanced or metastatic NSCLC after platinum therapy failure; andwith cisplatin for unresectable, locally advanced or metastaticuntreated NSCLC (1.2) Hormone Refractory Prostate Cancer (HRPC): with prednisone inandrogen independent (hormone refractory) metastatic prostate cancer(1.3) Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil foruntreated, advanced GC, including the gastroesophageal junction (1.4) Squamous Cell Carcinoma of the Head and Neck Cancer (SCCHN):with cisplatin and fluorouracil for induction treatment of locallyadvanced SCCHN (1.5)
DrugBank Targets:14 1. Tubulin beta-1 chain;2. Apoptosis regulator Bcl-2;3. Microtubule-associated protein 2;4. Microtubule-associated protein 4;5. Microtubule-associated protein tau;6. Nuclear receptor subfamily 1 group I member 2
Mechanism of Action:16 
Target: free tubulin
Action: promoter of assembly
FDA: Docetaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells that isessential for mitotic and interphase cellular functions. Docetaxel binds to free tubulin and promotes theassembly of tubulin into stable microtubules while simultaneously inhibiting their disassembly. Thisleads to the production of microtubule bundles without normal function and to the stabilization ofmicrotubules, which results in the inhibition of mitosis in cells. Docetaxel’s binding to microtubulesdoes not alter the number of protofilaments in the bound microtubules, a feature which differs from mostspindle poisons currently in clinical use.

Drugs for Gastric Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 355)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Capecitabineapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 11342154361-50-960953
Synonyms:
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
154361-50-9
158798-73-3
5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine
5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine
AC1L1U83
AC1Q4KU8
Ambap154361-50-9
C110904
C12650
C15H22FN3O6
CAPE
CAPECITABINE
CHEBI:31348
CHEMBL1773
CID60953
Capecitabin
Capecitabina
Capecitabine (JAN/USAN/INN)
Capecitabine [USAN]
Capecitabinum
Capecitibine
Capiibine
Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester
Caxeta
 
D01223
DB01101
FT-0082472
HSDB 7656
LS-59070
MolPort-005-938-254
N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
R-340
R340
RG-340
Ro 09-1978
Ro 09-1978/000
Ro-09-1978
Ro-09-1978/000
S1156_Selleck
UNII-6804DJ8Z9U
Xabine
Xeloda
Xeloda (TN)
Xeloda, Captabin, Capecitabine
ZINC03806413
capecitabina
capecitabine
capecitabinum
pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate
2
Propranololapproved, investigationalPhase 4228525-66-64946
Synonyms:
(+-)-Propranolol
(1)-1-(Isopropylamino)-3-(naphthyloxy)propan-2-ol
(R)-(+)-propranolol
(S)-(-)-PROPRANOLOL
1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol
1-(1-Naphthyloxy)-2-hydroxy-3-(isopropylamino)propane
1-(Isopropylamino)-3-(1-naphthoxy)-propan-2-ol
1-(Isopropylamino)-3-(1-naphthyloxy)-2-propanol
1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol
1-(naphthalen-1-yloxy)-3-(propan-2-ylamino)propan-2-ol
1-Isopropylamino-3-(1-naphthyloxy)-2-propanol
1-[(1-methylethyl)amino]-3-(naphthalen-1-yloxy)propan-2-ol
1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol
13013-17-7
2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)- (9CI)
2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-, (+-)- (9CI)
3-(naphthalen-1-yloxy)-1-(propan-2-ylamino)propan-2-ol
4199-09-1
4199-10-4
525-66-6
AB00053537
AC1L1JA4
AC1Q1QBV
AC1Q1QC0
AKOS000588816
AY 64043
AY-20694
Anaprilin
Anapriline
Angilol
Apsolol
Avlocardyl
BPBio1_001040
BRD-A10070317-003-06-9
BSPBio_000944
BSPBio_002682
Bedranol
Beprane
Berkolol
Beta Neg
Beta-Neg
Beta-Propranolol
Beta-Tablinen
Beta-Timelets
Betachron
Betadren
Betalong
Bio-0732
Bio1_000367
Bio1_000856
Bio1_001345
C07407
C16H21NO2
CBDivE_006180
CCRIS 3082
CHEBI:8499
CHEMBL27
CID4946
Cardinol
Caridolol
Corpendol
D,L-Propranolol
D08443
DB00571
DL-Propranolol hydrochloride
Deralin
DivK1c_000023
Dl-Propranolol Hydrochloride
Dociton
Duranol
EINECS 208-378-0
EINECS 235-867-6
Efektolol
Elbrol
Etalong
Euprovasin
Frekven
HMS2090L21
Herzbase
ICI 45520
IDI1_000023
INDERIDE-40/25
INDERIDE-80/25
Ikopal
Inderal
Inderal La
Inderal hydrochloride
Inderalici
Inderex
Inderide
Inderol
Indobloc
InnoPranXL
 
Innopran XL
Intermigran
KBio1_000023
KBio2_002515
KBio2_005083
KBio2_007651
KBio3_001766
KBio3_001902
KBio3_002993
KBioGR_001347
KBioGR_001684
KBioGR_002515
KBioSS_002523
Kemi
Kemi S
L000679
LS-122410
LS-184129
Lopac0_000896
Migrastat
MolPort-001-794-623
NCGC00015798-07
NCGC00024690-02
NCGC00024690-03
NINDS_000023
NSC91523
Naprilin
Obsidan
Obzidan
Oposim
Oprea1_304193
PDSP1_000767
PDSP1_001607
PDSP1_001608
PDSP2_000755
PDSP2_001591
PDSP2_001592
Prano-Puren
Pranolol
Prestwick0_000952
Prestwick1_000952
Prestwick2_000952
Prestwick3_000952
Pronovan
Propanalol
Propanix
Propanolol
Propanolol [INN-Spanish]
Prophylux
Propranalol
Propranolol
Propranolol (INN)
Propranolol (TN)
Propranolol Hcl
Propranolol Hcl Intensol
Propranolol Hydrochloride
Propranolol [INN:BAN]
Propranololo
Propranololo [DCIT]
Propranololum
Propranololum [INN-Latin]
Propranur
Proprasylyt
Pylapron
R,S-Propranolol Hydrochloride
Racemic propranolol
Rapynogen
Reducor
Reducor Line
Reducor line
SPBio_001361
SPBio_001658
SPBio_003093
STK735510
Sagittol
Sawatal
Servanolol
Sloprolol
Spectrum2_001301
Spectrum2_001699
Spectrum3_000883
Spectrum3_001071
Spectrum4_000974
Spectrum4_001222
Spectrum5_000751
Sumial
Tesnol
UNII-9Y8NXQ24VQ
b-Propranolol
beta-Propranolol
cMAP_000071
etalong
propranolol
propranololo
β-Propranolol
3
Oxaliplatinapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1146061825-94-35310940, 9887054, 6857599, 9887054, 43805
Synonyms:
CHEMBL1201055
CID9887054
D01790
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatin (TN)
Elplat
Foloxatine
L-OHP
Oxalatoplatin
 
Oxalatoplatinum
Oxaliplatin (JAN/USAN/INN)
Oxaliplatin [Usan:Inn:Ban]
Oxaliplatino [Spanish]
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
Transplatin
oxaliplatin
oxaliplatine
oxaliplatino
oxaliplatinum
4
Irinotecanapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1112397682-44-5, 100286-90-660838
Synonyms:
(+)-Irinotecan
(4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE
(4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate
1u65
97682-44-5
AC-7469
AC1L1U0Z
AC1Q6PGI
BRD-K08547377-003-02-4
BSPBio_002346
Bio-0054
Biotecan
Biotecan (TN)
C16641
C33H38N4O6
CHEBI:105985
CHEMBL481
CID60838
CP0
Campothecin-11
Campto
Camptosar
 
Camptosar, Campto, CPT-11, Irinotecan
Camptothecin-11
D08086
DB00762
FT-0083650
HSDB 7607
IRINOTECAN HYDROCHLORIDE Trihydrate
IRINOTECAN, CPT-11
Irinotecan (INN)
Irinotecan Hcl
Irinotecan Hydrochloride
Irinotecan Hydrochloride Trihydrate
Irinotecan [INN:BAN]
Irinotecan hydrochloride
Irinotecanum
Irinotecanum [INN-Latin]
LS-44589
NCI60_005051
NSC728073
S1198_Selleck
TL8006026
UNII-7673326042
irinotecan
5
FluorouracilapprovedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1185651-21-83385
Synonyms:
1-fluoro-1h-pyrimidine-2,4-dione
1004-03-1
1upf
2,4-Dihydroxy-5-fluoropyrimidine
2,4-Dioxo-5-fluoropryimidine
2,4-Dioxo-5-fluoropyrimidine
47576_FLUKA
4921-97-5
5 FU Lederle
5 FU medac
5 Fluorouracil
5 Fluorouracil biosyn
5 HU Hexal
5-FU
5-FU (TN)
5-FU Lederle
5-FU medac
5-Faracil
5-Fluor-2,4(1H,3H)-pyrimidindion
5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]
5-Fluor-2,4-dihydroxypyrimidin
5-Fluor-2,4-dihydroxypyrimidin [Czech]
5-Fluor-2,4-pyrimidindiol
5-Fluor-2,4-pyrimidindiol [Czech]
5-Fluoracil
5-Fluoracil [German]
5-Fluoracyl
5-Fluoro-2,4(1H,3H)-pyrimidinedione
5-Fluoro-2,4-pyrimidinedione
5-Fluoropyrimidin-2,4-diol
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluoruracil
5-Fluoruracil [German]
5-Fluracil
5-Ftouracyl
5-HU Hexal
5-fluoro uracil
5-fluoro-1H-pyrimidine-2,4-dione
5-fluoropyrimidine-2,4(1H,3H)-dione
5-fluorouracil
51-21-8
5FU
79108-01-3
AC-11201
AC1L1FTE
AC1Q4N2X
AI3-25297
AKOS000119162
AKOS003237897
AccuSite
Actino-Hermal
Adrucil
Adrucil (TN)
Allergan Brand of Fluorouracil
Arumel
BB_NC-0576
BSPBio_002048
C07649
C4H3FN2O2
CCRIS 2582
CHEBI:46345
CHEMBL185
CID3385
CPD0-1327
CPD000038082
CSP Brand of Fluorouracil
Carac
Carac (TN)
Carzonal
Cinco FU
Cytosafe
D005472
D00584
DB00544
Dakota Brand of Fluorouracil
Dakota, Fluorouracile
Dermatech Brand of Fluorouracil
Dermik Brand of Fluorouracil
DivK1c_000054
EINECS 200-085-6
EU-0100536
Effluderm
Effluderm (free base)
Efudex
Efudix
Efurix
F 6627
F0151
F6627_SIGMA
F8423_SIGMA
FT-0082524
FU
Ferrer Brand of Fluorouracil
Fiverocil
Fluoro Uracil
Fluoro Uracile ICN
Fluoro-Uracile ICN
Fluoro-uracile
Fluoro-uracilo
Fluoroblastin
Fluoroplex
Fluoroplex (TN)
Fluorouracil
Fluorouracil (JP15/USP/INN)
Fluorouracil GRY
Fluorouracil Mononitrate
Fluorouracil Monopotassium Salt
Fluorouracil Monosodium Salt
Fluorouracil Potassium Salt
Fluorouracil Teva Brand
Fluorouracil [USAN:INN:BAN:JAN]
 
Fluorouracil-GRY
Fluorouracile
Fluorouracile Dakota
Fluorouracile [DCIT]
Fluorouracilo
Fluorouracilo Ferrer Far
Fluorouracilo [INN-Spanish]
Fluorouracilum
Fluorouracilum [INN-Latin]
Fluoruracil
Fluouracil
Flurablastin
Fluracedyl
Fluracil
Fluracilum
Fluri
Fluril
Fluro Uracil
Fluroblastin
Flurodex
Flurouracil
Flurox
Ftoruracil
Gry Brand of Fluorouracil
HMS1920O18
HMS2090I04
HMS2091F19
HMS500C16
HSDB 3228
Haemato Brand of Fluorouracil
Haemato fu
Haemato-fu
Hexal Brand of Fluorouracil
I07-0022
ICN Brand of Fluorouracil
IDI1_000054
IN1335
KBio1_000054
KBio2_001321
KBio2_003889
KBio2_006457
KBio3_001268
KBioGR_001253
KBioSS_001321
Kecimeton
LS-153
Lopac-F-6627
Lopac0_000536
MLS000069498
MLS002415705
MolPort-000-156-102
MolPort-003-990-447
MolPort-004-758-143
MolPort-004-758-144
MolPort-005-861-486
NCGC00015442-01
NCGC00015442-03
NCGC00015442-10
NCGC00091349-01
NCGC00091349-02
NCGC00091349-03
NCGC00091349-04
NCGC00091349-05
NCGC00091349-07
NCGC00091349-08
NCI60_001652
NINDS_000054
NSC 19893
NSC-19893
NSC19893
Neocorp Brand of Fluorouracil
Neofluor
Onkofluor
Onkoworks Brand of Fluorouracil
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Riemser Brand of Fluorouracil
Ro 2-9757
Ro-2-9757
Roche Brand of Fluorouracil
S1209_Selleck
SAM002264615
SMR000038082
SPBio_000291
SPECTRUM1500305
STK297802
Spectrum2_000076
Spectrum3_000434
Spectrum4_000557
Spectrum5_000718
Spectrum_000841
T5233394
TL8006093
Teva Brand of Fluorouracil
Timazin
U 8953
U-8953
UNII-U3P01618RT
UPCMLD-DP130
UPCMLD-DP130:001
URF
Ulup
WLN: T6MVMVJ EF
ZINC00897110
biosyn Brand of Fluorouracil
fluorouracil
inhibits thymilidate synthetase
medac Brand of Fluorouracil
nchembio.90-comp3
nchembio809-comp6
ribosepharm Brand of Fluorouracil
tetratogen
6
Amoxicillinapproved, vet_approvedPhase 446526787-78-033613, 2171
Synonyms:
(-)-6-(2-Amino-2-(P-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo-(3.2.0)heptane-2-carboxylic acid
(2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
(2S,5R,6R)-6-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
26787-78-0
33911-69-2
34642-77-8 (mono-hydrochloride salt)
4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(2-amino-2-(p-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-, D- (8CI)
6-(D-(-)-alpha-Amino-p-hydroxyphenylacetamido)penicillanic acid
6-(D-(-)-p-Hydroxy-alpha-aminobenzyl)penicillin
6-(a-Amino-4-hydroxyphenylacetamido)penicillanic acid
6-(p-Hydroxy-alpha-aminophenylacetamido)penicillanic acid
6-(p-hydroxy-α-aminophenylacetamido)penicillanic acid
6-[[Amino(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 9CI
61336-70-7 (TRIHYDRATE)
6beta-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-2,2-dimethylpenam-3alpha-carbonyl
6beta-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-2,2-dimethylpenam-3alpha-carboxylic acid
71447-36-4
81030-75-3
AC-12263
AC1L1PY2
AMC
AMOXICILLIN CRYSTALLINE
AMOXICILLIN PEDIATRIC
AMPC
AUGMENTIN '125'
AUGMENTIN '200'
AUGMENTIN '250'
AUGMENTIN '400'
AUGMENTIN '500'
AUGMENTIN '875'
AUGMENTIN ES-600
AX
Actimoxi
Almodan
Ambap26787-78-0
Amix
Amoclen
Amolin
Amopen
Amopenixin
Amoram
Amox
Amox 250 Cap 250mg
Amox 500 Cap 500mg
Amox S 125 Sus 125mg/5ml
Amox S 250 Sus 250mg/5ml
Amoxi
Amoxi-Mast
Amoxi-mast
Amoxibiotic
Amoxicaps
Amoxicilina
Amoxicilina [INN-Spanish]
Amoxicillin (INN)
Amoxicillin (TN)
Amoxicillin (anhydrous)
Amoxicillin (inn)
Amoxicillin Trihydrate
Amoxicillin and clavulanate potassium
Amoxicillin anhydrous
Amoxicillin pediatric
Amoxicillin trihydrate
Amoxicillin(usan)
Amoxicilline
Amoxicilline [INN-French]
Amoxicilline [INN]
Amoxicilline [inn]
Amoxicillinum
Amoxicillinum [INN-Latin]
Amoxid
Amoxiden
Amoxil
Amoxivet
Amoxycillin
Amoxycillin Trihydrate
Amoxycillin trihydrate
Amoxycillin, BAN
Amoxymed
Amrit
Anemolin
Apo-Amoxi
Apo-Amoxi Cap 250mg
Apo-Amoxi Cap 500mg
Apo-Amoxi Pwr for Susp 125mg/5ml
Apo-Amoxi Pwr for Susp 250mg/5ml
Apo-amoxi
Apo-amoxi sugar free
Aspenil
BL-P 1410
BLP 1410
BPBio1_000499
BRD-K55044200-001-03-9
BRL 2333
BRL-2333
BSPBio_000453
 
Biomox
Bristamox
C06827
CHEBI:2676
CHEBI:53712
CHEMBL1082
CID33613
CPD000058707
Cemoxin
Clamoxyl
Clamoxyl (SKB)
D-(-)-alpha-Amino-p-hydroxybenzyl penicillin
D-(-)-alpha-Amino-p-hydroxybenzylpenicillin
D-(alpha-Amino-p-hydroxybenzyl)penicillin
D-2-Amino-2-(4-hydroxyphenyl)acetamidopenicillanic acid
D-Amoxicillin
D07452
DB01060
Delacillin
DisperMox
Dispermox
EINECS 248-003-8
Efpenix
Flemoxin
Galenamox
Gen-Amoxicillin 250mg
Gen-Amoxicillin 500mg
HMS1569G15
HSDB 3204
Hiconcil
Histocillin
Hydroxyampicillin
Ibiamox
Imacillin
LS-149721
Lamoxy
Larotid
MLS000028632
MLS002222248
Metafarma capsules
Metifarma capsules
MolPort-003-981-182
MolPort-005-933-687
Moxacin
Moxal
Moxatag
NCGC00179554-01
NSC 277174
NSC277174
Novamoxin Cap 250mg
Novamoxin Cap 500mg
Novamoxin Sus 125mg/5ml
Novamoxin Sus 250mg/5ml
Nu-Amoxi Cap 250mg
Nu-Amoxi Cap 500mg
Nu-Amoxi Sus 125/5ml
Nu-Amoxi Sus 250mg/5ml
Ospamox
P-Hydroxyampicillin
PHL-amoxicillin
PMS-amoxicillin
Pamoxicillin
Piramox
Polymox
Prestwick0_000357
Prestwick1_000357
Prestwick2_000357
Prestwick3_000357
Prestwick_713
Prevpac
Pro Amox Pwr for Oral Susp 125mg/5ml
Pro Amox-250 Cap 250mg
Pro Amox-500 Cap 500mg
Pro-Amox-250 Orl Sus 250mg/5ml
R-Hydroxyampicillin
Rimoxallin
Ro 10-8756
Robamox
SAM002264592
SMR000058707
SPBio_002374
Sauracillin
Sawamox PM
Sumox
Tolodina
Trimox
Unicillin
Utimox
Vetramox
Wymox
Zimox
alpha-Amino-p-hydroxybenzylpenicillin
amoxicillanyl
amoxicillin
p-Hydroxyampicillin
α-amino-p-hydroxybenzylpenicillin
7
LevoleucovorinapprovedPhase 4, Phase 3, Phase 2, Phase 172868538-85-2
Synonyms:
(6S)-5-Formyl-5,6,7,8-tetrahydrofolic acid
(6S)-5-formyltetrahydrofolic acid
(6S)-Folinic acid
(6S)-Leucovorin
 
(S)-Leucovorin
Citrovorum factor
L-Folinic acid
Levofolene
Levofolinic acid
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamic acid
8
MetronidazoleapprovedPhase 4, Phase 1486443-48-14173
Synonyms:
1-(2-hydroxy-1-ethyl)-2-methyl-5-nitroimidazole
1-(2-hydroxyethyl)-2-methyl-5-nitroimidazole
1-(beta-Ethylol)-2-methyl-5-nitro-3-azapyrrole
1-(beta-Hydroxyethyl)-2-methyl-5-nitroimidazole
1-(beta-Oxyethyl)-2-methyl-5-nitroimidazole
1-(β-ethylol)-2-methyl-5-nitro-3-azapyrrole
1-(β-hydroxyethyl)-2-methyl-5-nitroimidazole
1-(β-oxyethyl)-2-methyl-5-nitroimidazole
1-Hydroxyethyl-2-methyl-5-nitroimidazole
2-(2-methyl-5-nitroimidazol-1-yl)ethanol
2-Methyl-5-nitro-1-imidazoleethanol
2-Methyl-5-nitroimidazole-1-ethanol
2-methyl-1-(2-hydroxyethyl)-5-nitroimidazole
2-methyl-3-(2-hydroxyethyl)-4-nitroimidazole
2-methyl-5-nitroimidazole-1-ethanol
443-48-1
46461_FLUKA
46461_RIEDEL
69198-10-3 (mono-hydrochloride)
99616-64-5
AB00052046
AC-10556
AC1L1HKS
AC1Q2P2Z
AKOS000269646
APMN
ARONIS24285
Acromona
Anagiardil
Apo-Metronidazole
Arilin
Atrivyl
BAS 02983617
BAY-5360
BCBcMAP01_000184
BIDD:GT0107
BPBio1_000004
BRD-K52020312-001-05-2
BRN 0611683
BSPBio_000002
BSPBio_002031
Bayer 5360
Bexon
Bio-0694
CAS-443-48-1
CB-01-14 MMX
CCRIS 410
CHEBI:39845
CHEBI:6909
CHEMBL137
CID4173
CONT
CPD000058175
Caswell No. 579AA
Clont
D00409
DB00916
Danizol
Deflamon
Deflamon-wirkstoff
DivK1c_000007
EINECS 207-136-1
EPA Pesticide Chemical Code 120401
Efloran
Elyzol
Entizol
Eumin
FLAGYL I.V. RTU IN PLASTIC CONTAINER
Flagemona
Flagesol
Flagil
Flagyl
Flagyl (TN)
Flagyl 375
Flagyl Er
Flagyl I.V.
Flagyl I.V. RTU
Flegyl
Florazole
Fossyol
Giatricol
Ginefla vir
Gineflavir
HMS1568A04
HMS1920N19
HMS2051G07
HMS2090B19
HMS2091F14
HMS500A09
HMS547C19
HSDB 3129
I14-0667
IDI1_000007
IDR-90105
KBio1_000007
KBio2_001515
KBio2_004083
KBio2_006651
KBio3_001531
KBioGR_000559
KBioSS_001515
Klion
Klont
LS-1264
M0924
M1547_SIGMA
M3761_FLUKA
M3761_SIGMA
M9036_SIGMA
METRO I.V
METRONIDAZOLE USP
MLS000028590
MLS000758286
Maybridge1_001999
Meronidal
Methronidazole
Methyl-5-nitroimidazole-1-ethanol
 
Metric
Metric 21
Metro Cream
Metro Gel
Metro I.V.
Metro I.V. In Plastic Container
MetroCream
MetroGel
MetroGel-Vaginal
MetroLotion
Metrodzhil
Metrogel-vaginal (TN)
Metrogyl
Metrolag
Metrolyl
Metromidol
Metronidaz
Metronidazol
Metronidazol [INN-Spanish]
Metronidazole (JP15/USP/INN)
Metronidazole Benzoate
Metronidazole Monohydrochloride
Metronidazole Phosphoester
Metronidazole [USAN:INN:BAN:JAN]
Metronidazole in Plastic Container
Metronidazolo
Metronidazolo [DCIT]
Metronidazolum
Metronidazolum [INN-Latin]
Metrotop
Metrozine
Metryl
Mexibol
Mexibol 'silanes'
MolPort-000-141-892
MolPort-002-502-101
Monagyl
Monasin
NCGC00016446-01
NCGC00016446-02
NCGC00022059-03
NCGC00022059-04
NCGC00022059-05
NCIOpen2_000337
NIDA
NINDS_000007
NSC 50364
NSC 69587
NSC-50364
NSC50364
NSC69587
Nalox
Nidagel
Noritate
Noritate (TN)
Novonidazol
Orvagil
Prestwick0_000081
Prestwick1_000081
Prestwick2_000081
Prestwick3_000081
Prestwick_334
Protostat
RP 8823
RP-8823
Rathimed
Rosased
S1907_Selleck
SAM001247010
SBB041018
SC 10295
SMP1_000189
SMR000058175
SPBio_000666
SPBio_001941
SPECTRUM1500412
STK177359
Sanatrichom
Satric
Spectrum2_000883
Spectrum3_000506
Spectrum4_000060
Spectrum5_001289
Spectrum_001035
Takimetol
Trichazol
Trichex
Tricho cordes
Tricho-gynaedron
Trichocide
Trichomol
Trichomonacid 'pharmachim'
Trichopal
Trichopol
Tricocet
Tricom
Tricowas B
Trikacide
Trikamon
Trikojol
Trikozol
Trimeks
Trivazol
UNII-140QMO216E
Vagilen
Vagimid
Vandazole
Vertisal
WLN: T5N CNJ A2Q B1 ENW
WLN: T5N CNJA2Q B1 ENW
WLN: T6NTJ DQ ANU1- ET5N CNJ A1 BNW
Wagitran
ZERO/004064
ZINC00113442
Zadstat
Zidoval
giniflavir
metronidazole
neo-Tric
9
Trastuzumabapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1784180288-69-19903
Synonyms:
180288-69-1
Anti HER2
Anti-erbB2 Monoclonal Antibody
D03257
HER2 Monoclonal Antibody
Herceptin
 
Herceptin (TN)
Ig gamma-1 chain C region
Trastuzumab
Trastuzumab (INN)
Trastuzumab (genetical recombination)
Trastuzumab (genetical recombination) (JAN)
trastuzumab
10
ClarithromycinapprovedPhase 428981103-11-984029
Synonyms:
(14R)-14-Hydroxyclarithromycin
116836-41-0
6-O-Methylerythromycin
6-O-Methylerythromycin a
6-O-methyl erythromycin
81103-11-9
A-56268
AC-6813
AC1L1HJO
AC1L36NJ
AC1NFSZE
AC1NR4MY
AC1NSJWH
AC1O52DV
AC1Q6O1T
ANX-015
Abbotic
Abbott-56268
Adel
Astromen
BB_NC-1450
BIDD:GT0200
BSPBio_003453
Biaxin
Biaxin (TN)
Biaxin HP
Biaxin XL
Biaxin filmtab
Biaxin xl filmtab
Bicrolid
Bio-0020
C06912
C2220
C30H54O11.C9H19NO2
CCRIS 8833
CHEBI:136451
CHEBI:3732
CHEMBL143
CHEMBL1741
CID10147055
CID10328822
CID11814635
CID11828745
CID11969952
CID4663848
CID489010
CID5284534
CID5311050
CID54688
CID6426662
CID84029
CID9810688
CID9811194
CLA
CLARITHROMYCIN
CLM & IL-12
CPD000466382
CRL-1605 & Clarithromycin
CTY
Clacine
Clambiotic
Claribid
Claricide
Clarith
Clarithromycin & Interleukin-12
Clarithromycin (JP15/USP/INN)
Clarithromycin [USAN:INN:BAN:JAN]
Clarithromycin extended release
Clarithromycin suspension or tablets
Clarithromycina
Clarithromycine
Clarithromycine [INN-French]
 
Clarithromycinum
Clarithromycinum [INN-Latin]
Claritromicina
Claritromicina [INN-Spanish]
Clathromycin
Cyllid
Cyllind
D00276
DRG-0099
DivK1c_006655
HMS1922H09
HMS2051G18
HMS2090O11
HMS2094M05
Helas
Heliclar
I05-0074
KBio1_001599
KBio2_000509
KBio2_003077
KBio2_005645
KBio3_002673
KBioGR_001218
KBioSS_000509
Klacid
Klaciped
Klaricid
Klaricid H.P
Klaricid H.P.
Klaricid Pediatric
Klaricid XL
Klarid
Klarin
Klax
Kofron
LMPK04000014
LS-1812
Lactoferrin B & Clarithromycin
Lactoferrin H & Clarithromycin
MLS000759516
MLS001201751
MLS001424066
Mabicrol
Macladin
Maclar
Mavid
MolPort-002-507-425
MolPort-003-845-969
MolPort-005-910-192
MolPort-005-934-146
NCGC00178054-01
NSC643733
Naxy
O(6)-methylerythromycin
SAM001246748
SDP-015
SMR000466382
SPBio_001855
SPECTRUM1504231
STK801952
SpecPlus_000559
Spectrum2_001668
Spectrum3_001667
Spectrum4_000629
Spectrum5_001729
Spectrum_000089
TE-031
TE031
UNII-H1250JIK0A
Veclam
Zeclar
clarithromycin
clarithromycina
hydro-2H-pyran-2-yl]oxy}-7-methoxy-3,5,7,9,11,13-hexame
11
NicotineapprovedPhase 4110354-11-5942, 89594
Synonyms:
(−
(+)-Nicotine
(-)-3-(1-Methyl-2-pyrrolidyl)pyridine
(-)-3-(N-Methylpyrrolidino)pyridine
(-)-Nicotine
(-)-Nicotine solution
(2S) 3-(1-Methyl-pyrrolidin-2-yl)-pyridine
(R)-3-(1-Methyl-2-pyrrolidinyl)pyridine
(R,S)-Nicotine
(S)-(-)-NICOTINE, 3-[(2S)-1-METHYL-2-PYRROLIDINYL] PYRIDINE
(S)-(-)-Nicotine
(S)-(−)-nicotine
(S)-3-(1-methylpyrrolidin-2-yl)pyridine
(S)-3-(N-methylpyrrolidin-2-yl)pyridine
(S)-Nicotine
(−)-nicotine
)-1-Methyl-2-(3-pyridyl)pyrrolidine
)-Nicotine
)-Nicotine solution
1-Methyl-2-(3-pyridal)-Pyrrolidine
1-Methyl-2-(3-pyridal)-pyrrolidene
1-Methyl-2-(3-pyridiyl)pyrrolidine
1-Methyl-2-(3-pyridyl)pyrrolidine
1uw6
2'-beta-H-Nicotine
3-(1-Methyl-2-pyrollidinyl)pyridine
3-(1-Methyl-2-pyrrolidinyl)-Pyridine
3-(1-Methyl-2-pyrrolidinyl)pyridine
3-(1-Methylpyrrolidin-2-yl)pyridine
3-(2-(N-methylpyrrolidinyl))pyridine
3-(N-Methylpyrollidino)pyridine
3-(N-Methylpyrrolidino)pyridine
3-(N-methylpyrollidino)pyridine
3-N-Methylpyrrolidine
3-[(2S)-1-methylpyrrolidin-2-yl]pyridine
36733_FLUKA
36733_RIEDEL
434F7990-3240-4A43-ACEC-E6CC1E495FA0
46343_FLUKA
46343_RIEDEL
54-11-5
AC1L3I79
AC1Q3ZOC
AI3-03424
BB_NC-0777
BIDD:GT0599
BRD-K05395900-322-02-1
Black Leaf
Black Leaf 40
C00745
CCRIS 1637
CHEBI:17688
CHEMBL3
CID89594
CPD000059074
Campbell's Nico-Soap
Caswell No. 597
Commit
D-Nicotine
D03365
DL-tetrahydronicotyrine
Destruxol
Destruxol Orchid Spray
EINECS 200-193-3
ENT 3,424
EPA Pesticide Chemical Code 056702
Emo-Nik
Flux Maag
Fumeto bac
Fumetobac
HSDB 1107
Habitrol
Habitrol (TN)
L(-)-nicotine
L(−)-nicotine
L-3-(1-Methyl-2-pyrrolidyl)pyridine
 
L-Nicotine
LS-202
MLS001055457
MLS001335905
Mach-Nic
Methyl-2-pyrrolidinyl)pyridine
Micotine
MolPort-000-744-731
N3876_SIGMA
N5511_FLUKA
N5511_SIGMA
NCGC00090693-01
NCGC00090693-02
NCGC00090693-03
NCGC00090693-04
NCGC00090693-05
NCGC00090693-06
NCGC00090693-07
NCT
NICOTINE AND SALTS
NSC 5065
NSC97238
Niagara P.A. Dust
Nic-Sal
Nico-Dust
Nico-Fume
Nicocide
Nicoderm
Nicoderm Cq
Nicoderm Patch
Nicorette
Nicorette Plus
Nicotin
Nicotina
Nicotina [Italian]
Nicotine
Nicotine (USP)
Nicotine (compounds related to)
Nicotine Alkaloid
Nicotine Patch
Nicotine Polacrilex
Nicotine [BSI:ISO]
Nicotine [UN1654]
Nicotine [UN1654] [Poison]
Nicotine [USAN]
Nicotrol
Nicotrol Inhaler
Nicotrol Ns
Nictoine patch
Nikotin
Nikotin [German]
Nikotyna
Nikotyna [Polish]
Ortho N-4 Dust
Ortho N-5 Dust
PDSP1_000113
PDSP1_000465
PDSP2_000463
PDSP2_000555
Prostep
R)-(+)-Nicotine
RCRA waste no. P075
RCRA waste number P075
SAM002564224
SDCCGMLS-0066911.P001
SMR000059074
Tendust
Transdermal Nicotine
UN1654
a -N-Methylpyrrolidine
a-N-Methylpyrrolidine
alpha-N-Methylpyrrolidine
beta-Pyridyl-alpha-N-methyl pyrrolidine
beta-Pyridyl-alpha-N-methylpyrrolidine
bmse000105
delta-Nicotine
nicotine
nicotine replacement patch
12
Lansoprazoleapproved, investigationalPhase 4218103577-45-33883
Synonyms:
103577-45-3
2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole
2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl)sulfinyl)benzimidazole
2-(((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl)sulfinyl)-1H-benzimidazole
2-({[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole
2-[({3-methyl-4-[(2,2,2-trifluoroethyl)oxy]pyridin-2-yl}methyl)sulfinyl]-1H-benzimidazole
2-[[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole
2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl] methyl] sulfinyl] benzimidazole
2-[[[3-methyl-4-(2,2,2-trifluroethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole
A 65006
A-65006
AB00052388
ABT-006
AC1L1GX8
AG 1749
AG-1749
Abbot Brand of Lansoprazole
Agopton
Almirall Brand of Lansoprazole
Amarin
Aprazol
BIDD:GT0006
BPBio1_001194
BRD-A49172652-001-05-7
BRN 4333393
BSPBio_001084
BSPBio_001830
Bamalite
Bio-0824
Biuret
Biuret Gr
Biuret Reagent
Biuret Reagent Solution
Blason
C058687
C16H14F3N3O2S
CAS-103577-45-3
CG-4801
CHEBI:6375
CHEMBL480
CID3883
CPD000058469
Compraz
D00355
DB00448
Dakar
DivK1c_000920
EU-0100709
FT-0082011
HMS1571G06
HMS1922M04
HMS2052F05
HMS2093M07
HMS502N22
HSDB 7204
Hoechst Brand of Lansoprazole
Hormona Brand of Lansoprazole
I06-0018
IDI1_000920
Ilsatec
KBio1_000920
KBio2_002060
KBio2_004628
KBio2_007196
KBio3_001330
KBioGR_001491
KBioSS_002060
Ketian
L 8533
L8533_SIGMA
LS-33080
Lancid
Lanfast
Lanproton
Lansopep
Lansophed
Lansoprazol
Lansoprazol [INN-Spanish]
Lansoprazole
Lansoprazole (JAN/USP/INN)
Lansoprazole [USAN:BAN:INN]
Lansoprazole [Usan:Ban:Inn]
Lansoprazolum
Lansoprazolum [INN-Latin]
Lansox
Lanston
 
Lanz
Lanzo
Lanzol
Lanzol-30
Lanzopral
Lanzor
Lanzul
Lapraz
Lasoprol
Lederle Brand of Lansoprazole
Limpidex
Linamarin
Lopac-L-8533
Lopac0_000709
MLS-0003247.0001
MLS000069705
MLS000759405
MLS001074170
Mesactol
MolPort-003-666-508
MolPort-006-394-760
Monolitum
NCGC00015615-01
NCGC00015615-02
NCGC00015615-03
NCGC00015615-06
NCGC00015615-11
NCGC00023826-03
NCGC00023826-04
NCGC00023826-05
NCGC00023826-06
NCGC00023826-07
NINDS_000920
Ogast
Ogastro
Opiren
Prestwick0_001072
Prestwick1_001072
Prestwick2_001072
Prestwick3_001072
PrevOnco
Prevacid
Prevacid (TN)
Prevacid I.V
Prevacid I.V.
Prevacid Iv
Prevacid SoluTab
Prevacid Solutab
Prevacid, Prevacid NapraPAC, Prevacid SoluTab, Lansoprazole
Prevpac
Prezal
Pro Ulco
Promeco
Promeco Brand of Lansoprazole
Promp
Prosogan
S1354_Selleck
SAM001246544
SMR000058469
SPBio_000488
SPBio_002992
SPECTRUM1503926
STK621169
Salvar Brand of Lansoprazole
Spectrum2_000444
Spectrum3_000295
Spectrum4_000856
Spectrum5_001521
Spectrum_001580
Suprecid
TAK 390MR
TAK-390MR
TAK390MR
TAP Brand of Lansoprazole
TL8000155
Takeda Brand of Lansoprazole
Takepron
Tecnobio Brand of Lansoprazole
UNII-0K5C5T2QPG
Ulpax
Vinas Brand of Lansoprazole
Wyeth Brand of Lansoprazole
Zoprol
Zoton
lansoprazole
lansoprazole sulphone
lanzoprazole
13
ZincapprovedPhase 4, Phase 222967440-66-632051, 23994
Synonyms:
30Zn
Cinc
Zinc
Zinc ion
 
Zincum
Zink
Zn
Zn(ii)
Zn2+
14
Rabeprazoleapproved, investigationalPhase 4156117976-89-35029
Synonyms:
117976-89-3
2-(((4-(3-Methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole
2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)-1H-benzimidazole
2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole
2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1H-benzimidazole
AC1L1JGC
AcipHex
Aciphex
BIDD:GT0019
C063129
C07864
C18H21N3O3S
CHEBI:8768
CHEMBL1219
CID5029
CL23619
CPD000469174
Clofezone
D08463
DB01129
Eraloc
Eraloc (TN)
 
HMS2052P03
HSDB 7321
Habeprazole
I06-0755
Irsogladine Maleate
LS-172365
LY307640
MLS001401446
MolPort-005-935-061
Pariet
Pariets
Rabeprazole
Rabeprazole (INN)
Rabeprazole [BAN:INN]
Rabeprazole [INN:BAN]
Rabeprazole sodium
Rebeprazole sodium
SAM001246619
SMR000469174
Sodium rabeprazole
UNII-32828355LL
dexrabeprazole
rabeprazole
rabeprazole sodium
15
SomatostatinapprovedPhase 4, Phase 3, Phase 1, Phase 2, Early Phase 123738916-34-6, 51110-01-153481605
Synonyms:
growth hormone-inhibiting hormone (GHIH)
 
somatotropin release-inhibiting factor (SRIF)
somatotropin release-inhibiting hormone
16
IronapprovedPhase 411657439-89-623925
Synonyms:
02583_FLUKA
12310_ALDRICH
12310_RIEDEL
129048-51-7
14067-02-8
161135-39-3
190454-13-8
195161-83-2
199281-22-6
209309_ALDRICH
209309_SIAL
255637_ALDRICH
266213_ALDRICH
266256_ALDRICH
267945_ALDRICH
267953_ALDRICH
26Fe
338141_ALDRICH
356808_ALDRICH
356824_ALDRICH
356832_ALDRICH
39344-71-3
3ZhP
413054_ALDRICH
443783-52-6
44890_ALDRICH
44890_FLUKA
675141-17-0
70884-35-4
73135-38-3
7439-89-6
8011-79-8
8053-60-9
AC1L2N38
ATW 230
ATW 432
Ancor B
Ancor en 80/150
Armco iron
Atomel 28
Atomel 300M200
Atomel 500M
Atomel 95
Atomiron 44MR
Atomiron 5M
Atomiron AFP 25
Atomiron AFP 5
C00023
C3518_SIAL
C3518_SIGMA
CCRIS 1580
CHEBI:18248
CID23925
Carbonyl iron
Copy Powder CS 105-175
D007501
DB01592
DSP 1000
DSP 128B
DSP 135
DSP 135C
DSP 138
Diseases (animal), iron overload
Diseases, iron overload
EF 1000
EF 250
EFV 200/300
EFV 250
EFV 250/400
EINECS 231-096-4
 
Ed-In-Sol
Eisen
Electrolytic iron
F 60 (metal)
FE
FT 3 (element)
Fe
Fe-40
Fe1+
Feronate
Ferretts
Ferro-Caps
Ferro-Time
Ferrousal
Ferrovac E
Ferrum
Ferrum metallicum
GS 6
HF 2 (element)
HL (iron)
HQ (metal)
HS (iron)
HS 4849
HSDB 604
Hemocyte
Hierro
Hoeganaes ATW 230
Hoeganaes EH
IRMM524A_FLUKA
IRMM524B_FLUKA
IRON
Iron (Fe)
Iron (Fe1+)
Iron ion (Fe+)
Iron ion(1+)
Iron monocation
Iron powder
Iron standard for AAS
Iron(1+)
Iron(1+) ion
Iron(III) nitrate solution
Iron, carbonyl
Iron, electrolytic
Iron, elemental
Iron, ion (Fe1+)
Iron, ion (Fe1+) (8CI,9CI)
Iron, reduced
LOHA
LS-3196
MolPort-003-925-001
NC 100
PZh-1M3
PZh-2
PZh1M1
PZh2M
PZh2M1
PZh2M2
PZh3
PZh3M
PZh4M
PZhO
Reduced iron
Remko
SUY-B 2
Siderol
UNII-E1UOL152H7
Vitedyn-Slo
Yieronia
fer
ferrous iron
hierro
17
leucovorinapproved, NutraceuticalPhase 4, Phase 3, Phase 2, Phase 1323558-05-954575, 6560146, 143
Synonyms:
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
(6R,S)-5-Formyltetrahydrofolate
10-Formyl-7,8-dihydrofolate
10-Formyl-7,8-dihydrofolic acid
5-Formyl-5,6,7,8-tetrahydrofolate
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
5-Formyltetrahydrofolate
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
5-formyltetrahydrofolic acid
Acide folinique
Calcium citrovorum factor
Calcium folinate
Citrovorum factor
Folinate
Folinic acid
Folinic acid calcium salt
 
Folinic acid calcium salt USP27
Folinic acid-SF
L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid
L-Leucovorin
L-N-[p-[[(2-Amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-Glutamic acid
L-leucovorin
Leucal
Leucovorin calcium
Leucovorin folinic acid
Leucovorinum
Leukovorin
Levoleucovorin
N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolate
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyl-THF
N5-Formyltetrahydrofolate
N5-Formyltetrahydrofolic acid
Welcovorin
Wellcovorin
folinate
18
Folic Acidapproved, nutraceutical, vet_approvedPhase 4, Phase 3, Phase 1, Phase 2439259-30-36037
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
AI3-26387
AKOS000503224
ARONIS014410
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
Antianemia factor
Apo-Folic
BIDD:ER0563
BIDD:GT0641
BIF0608
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
FOL
Facid
Factor U
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
Folsaeure
 
Folsan
Folsaure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
Incafolic
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
LS-2157
Liver Lactobacillus casei factor
MLS001304016
MLS001335861
Millafol
Mission prenatal
Mittafol
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-Pteroyl-L-glutamic acid
N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
NINDS_000494
NSC 3073
Nifolin
Nifolin [Denmark]
Novofolacid
Novofolacid [Canada]
PGA
PGA (VAN)
Prestwick3_000627
Prestwick_230
PteGlu
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylglutamate
Pteroylglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
SMP2_000137
SMR000471860
SPBio_001357
SPECTRUM1502020
Serum Folate Level
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
Spectrum_001381
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin B9
Vitamin Bc
Vitamin Be
Vitamin M
bmse000299
folic acid
nchembio.108-comp10
19
CamptothecinexperimentalPhase 4, Phase 2, Phase 17147689-03-4
Synonyms:
(+)-camptothecin
(+)-camptothecine
(s)-(+)-camptothecin
 
(s)-camptothecin
20(S)-Camptothecin
21,22-Secocamptothecin-21-oic acid lactone
Camptothecine
D-camptothecin
20VitaminsPhase 4, Phase 3, Phase 1, Phase 25282
21Vitamin B ComplexPhase 4, Phase 3, Phase 1, Phase 24337
22Protective AgentsPhase 4, Phase 3, Phase 2, Phase 17443
23Anti-Bacterial AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 111226
24AntidotesPhase 4, Phase 3, Phase 2, Phase 11071
25Calcium, DietaryPhase 4, Phase 3, Phase 2, Phase 15713
26Antiparasitic AgentsPhase 4, Phase 2, Phase 12199
27Trace ElementsPhase 4, Phase 3, Phase 1, Phase 26001
28MicronutrientsPhase 4, Phase 3, Phase 1, Phase 26001
29Topoisomerase InhibitorsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 15069
30HematinicsPhase 4, Phase 3, Phase 2, Phase 11684
31Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 122062
32Antiprotozoal AgentsPhase 4, Phase 2, Phase 12051
33Antihypertensive AgentsPhase 44207
34Neurotransmitter AgentsPhase 4, Phase 3, Phase 218340
35Cytochrome P-450 CYP3A InhibitorsPhase 41715
36Anti-Arrhythmia AgentsPhase 43093
37Adrenergic beta-AntagonistsPhase 41193
38Cytochrome P-450 Enzyme InhibitorsPhase 4, Phase 23917
39Adrenergic AgentsPhase 45352
40Adrenergic AntagonistsPhase 41573
41Vasodilator AgentsPhase 43543
42
LactitolPhase 4, Phase 1, Phase 2336585-86-43871
Synonyms:
4-O-b-D-Galactopyranosyl-D-glucitol, 9CI
E966
Emportal
 
Floralac
Importal
Oponaf
Portolac
43Antineoplastic Agents, PhytogenicPhase 4, Phase 3, Phase 2, Phase 15602
44Immunosuppressive AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 113086
45Liver ExtractsPhase 4, Phase 3, Phase 2, Phase 14067
46Antimetabolites, AntineoplasticPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 17361
47AntimetabolitesPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 112054
48topoisomerase I inhibitorsPhase 4, Phase 3, Phase 2, Phase 11370
49Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 113168
50Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 113180

Interventional clinical trials:

(show top 50)    (show all 683)
idNameStatusNCT IDPhase
1Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical PracticeUnknown statusNCT01273441Phase 4
2Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal CancerUnknown statusNCT00274885Phase 4
3Endoscopic Treatment Alone Versus Combined Propranolol and Endoscopic Treatment of Acute Variceal Hemorrhage in Patients With Hepatocellular CarcinomaUnknown statusNCT01451658Phase 4
4Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal VaricesUnknown statusNCT01970748Phase 4
5Effects of Oral Rabeprazole on the Prevention of Ulcer Bleeding Following Endoscopic Mucosal ResectionCompletedNCT00844675Phase 4
6Clinical Outcomes of Endoscopic Resection for Treating WHYX LesionCompletedNCT01451034Phase 4
7Phase II Trial Evaluating Irinotecan and Capecitabine Relapsed/Refractory Upper GI TumoursCompletedNCT00220168Phase 4
8Treatment of Zollinger-Ellison Syndrome With PrevacidCompletedNCT00204373Phase 4
9Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit SmokingCompletedNCT00365508Phase 4
10Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric CancerRecruitingNCT02426034Phase 4
11Iron Replacement in Oesophagogastric NeoplasiaRecruitingNCT01927328Phase 4
12Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach CancerRecruitingNCT02366819Phase 4
13Early Oral Versus Enteral Nutrition After PancreatoduodenectomyRecruitingNCT01642875Phase 4
14Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.RecruitingNCT01794793Phase 4
15Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine TumorsActive, not recruitingNCT02759718Phase 4
16Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent ChemoradiotherapyNot yet recruitingNCT02570529Phase 4
17Pharmacokinetic Study of Capecitabine After Total Gastrectomy for Stomach AdenocarcinomaTerminatedNCT00871273Phase 4
18A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric CancerTerminatedNCT01260194Phase 4
19Pasireotide Treatment for Neuroendocrine TumorWithdrawnNCT02779257Phase 4
20Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment in Metastatic Adenocarcinoma of the Stomach or Esophagogastric JunctionUnknown statusNCT01015339Phase 3
21Taxanes or Platinum in Combination With Capecitabine Followed by Capecitabine Alone as First Line Treatment for Patients With Advanced Adenocarcinoma of Stomach or Esophagogastric JunctionUnknown statusNCT01468389Phase 3
22SOX Regimen as Neoadjuvant Chemotherapy for AJCC Stage II-III Gastric CancerUnknown statusNCT01583361Phase 3
23Docetaxel and S1 (DS) Versus S1 and Cisplatin (SP) in Curatively Resected Stage IIIB/IV Gastric CancerUnknown statusNCT01283217Phase 3
24Surgery With or Without Combination Chemotherapy in Treating Patients With Cancer of the EsophagusUnknown statusNCT00002883Phase 3
25Endoscopy Every 2 Years or Only as Needed in Monitoring Patients With Barrett EsophagusUnknown statusNCT00987857Phase 3
26Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the StomachCompletedNCT01640782Phase 3
27Phase III Randomized Trial of Adjuvant XP Chemotherapy and XP/RT for Resected Gastric AdenocarcinomaCompletedNCT00323830Phase 3
28Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric CancerCompletedNCT00678535Phase 3
29Covered Versus Uncovered Self-expandable Metallic Stents for Malignant Gastric Outlet ObstructionCompletedNCT01646476Phase 3
30Symptom Control With or Without Docetaxel in Treating Patients With Relapsed Esophageal Cancer or Stomach CancerCompletedNCT00978549Phase 3
31Trial of Adjuvant Chemotherapy for Gastric CancerCompletedNCT00296335Phase 3
32Trial of Adjuvant Chemotherapy for Gastric CancerCompletedNCT00296322Phase 3
33A Study of Capecitabine (Xeloda) in Combination Chemotherapy Versus Surgery Alone in Participants With Gastric CancerCompletedNCT02560974Phase 3
34Capecitabine and Oxaliplatin Adjuvant Study in Stomach CancerCompletedNCT00411229Phase 3
35Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and AdenocarcinomaCompletedNCT00917384Phase 3
36Metastatic Gastric Cancer FFCD 03-07CompletedNCT00374036Phase 3
37S-1 and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage III Stomach CancerCompletedNCT00182611Phase 3
38A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal CancerCompletedNCT01662869Phase 3
39Surgery With or Without Combination Chemotherapy in Treating Patients With Stomach CancerCompletedNCT00002615Phase 3
40Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal CancerCompletedNCT00020787Phase 3
41Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)CompletedNCT00879333Phase 3
42Impact of Roux-En-Y Pouch Reconstruction Compared With Conventional Roux-En-Y Reconstruction on Health-Related Quality of Life in Patients Undergoing Total Gastrectomy for AdenocarcinomaCompletedNCT01491698Phase 3
43A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric CancerCompletedNCT00548548Phase 3
44Comparison of Efficacy and Frequency of Adverse Events of 1st Line Palliative Chemotherapy EOX and mDCF Regimens in Advanced HER2-negative Gastric CarcinomaCompletedNCT02445209Phase 3
45Phase III Study OF the Gastric Surgery on Advanced Stage Gastric CancerCompletedNCT00260884Phase 3
46A Randomised Trial of Preoperative Radiotherapy for Stage T3 Adenocarcinoma of RectumCompletedNCT00145769Phase 3
47Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the PancreasCompletedNCT00844649Phase 3
48Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison SyndromeCompletedNCT00079833Phase 3
49A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related DiseasesCompletedNCT02153398Phase 3
50Two Chemotherapy Regimens Compared With Observation in Treating Patients With Completely Resected Pancreatic CancerCompletedNCT00058201Phase 3

Search NIH Clinical Center for Gastric Adenocarcinoma

Genetic Tests for Gastric Adenocarcinoma

About this section

Anatomical Context for Gastric Adenocarcinoma

About this section

MalaCards organs/tissues related to Gastric Adenocarcinoma:

36
Lymph node, Breast, Colon, Endothelial, Liver, Lung, T cells

Publications for Gastric Adenocarcinoma

About this section

Articles related to Gastric Adenocarcinoma:

(show top 50)    (show all 1037)
idTitleAuthorsYear
1
Histopathological regression of gastric adenocarcinoma after neoadjuvant therapy: a critical review. (28044374)
2017
2
Prognostic significance of autophagy-related proteins expression in resected human gastric adenocarcinoma. (28224423)
2017
3
CDKN1A histone acetylation and gene expression relationship in gastric adenocarcinomas. (26567008)
2017
4
Expression of ribophorine II is a promising prognostic factor in human gastric adenocarcinoma. (28035352)
2017
5
Early gastric adenocarcinoma arising within foveolar-type dysplasia in a patient with Muir-Torre variant Lynch syndrome. (28501935)
2017
6
Clinicopathological evaluation of Sox10 expression in diffuse-type gastric adenocarcinoma. (27943102)
2017
7
MALAT1 promoted invasiveness of gastric adenocarcinoma. (28077118)
2017
8
CDH17 Is a More Sensitive Marker for Gastric Adenocarcinoma Than CK20 and CDX2. (28029907)
2017
9
Intraoperative Gastroscopy for Tumor Localization in Laparoscopic Surgery for Gastric Adenocarcinoma. (27584713)
2016
10
Efficacy of Omega Fatty Acid Supplementation on mRNA Expression Level of Tumor Necrosis Factor Alpha in Patients with Gastric Adenocarcinoma. (27170003)
2016
11
Concomitant multiple myeloma, gastric adenocarcinoma and Evan's syndrome in a patient presenting with anaemia. (27979847)
2016
12
SNP rs1059234 in CDKN1A Gene Correlates with Prognosis in Resected Gastric Adenocarcinoma. (27156331)
2016
13
Clinicopathological Features of Gastric Adenocarcinoma of the Fundic Gland (Chief Cell Predominant Type) by Retrospective and Prospective Analyses of Endoscopic Findings. (27129734)
2016
14
Decreased Dp71 expression is associated with gastric adenocarcinoma prognosis. (27449096)
2016
15
Elevated expression of Nodal and YAP1 is associated with poor prognosis of gastric adenocarcinoma. (27325246)
2016
16
Nuclear overexpression of the overexpressed in lung cancer 1 predicts worse prognosis in gastric adenocarcinoma. (28038462)
2016
17
Tumor volume of resectable gastric adenocarcinoma on multidetector computed tomography: association with N categories. (27166769)
2016
18
Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX). (27602586)
2016
19
Gastric adenocarcinoma of the fundic gland (chief cell-predominant type): A review of endoscopic and clinicopathological features. (28082804)
2016
20
Gastric Adenocarcinoma Presenting after Revisional Roux-en-Y Gastric Bypass. (27657561)
2016
21
Clinical significance of I^2-adrenergic receptor expression in patients with surgically resected gastric adenocarcinoma. (27485115)
2016
22
Gastric Adenocarcinoma in a Patient with X-Linked Agammaglobulinemia and HIV: Case Report and Review of the Literature. (27722150)
2016
23
Epigenetic changes of CDX2 in gastric adenocarcinoma. (27139434)
2016
24
Increased expression of IDO associates with poor postoperative clinical outcome of patients with gastric adenocarcinoma. (26887337)
2016
25
Growth inhibition of human gastric adenocarcinoma cells in vitro by STO-609 is independent of calcium/calmodulin-dependent protein kinase kinase-beta and adenosine monophosphate-activated protein kinase. (27158402)
2016
26
Gastric Adenocarcinoma of the Fundic Gland Type Treated by Endoscopic Mucosal Resection: A Case Report and Review of the Literature. (27994902)
2016
27
Beyond gastric adenocarcinoma: Multimodality assessment of common and uncommon gastric neoplasms. (27645897)
2016
28
The Value of Preoperative Neutrophil to Lymphocyte Ratio in Indicating Lymph Node Metastasis in Patients with Resectable T2 Stage Gastric Adenocarcinoma. (27215086)
2016
29
Presence of Epstein-Barr virus in gastric adenocarcinoma in Indian patients. (27514983)
2016
30
Clinicopathological characteristics and outcomes in stage I-III mucinous gastric adenocarcinoma: a retrospective study at a single medical center. (27112436)
2016
31
Twelve-year natural history of a gastric adenocarcinoma of fundic gland type. (27624750)
2016
32
Germ Cell Tumor Targeting Chemotherapy in Gastric Adenocarcinoma with an Endodermal Sinus Tumor Component: A Case Report. (27351795)
2016
33
The first European family with gastric adenocarcinoma and proximal polyposis of the stomach: case report and review ofA the literature. (27343414)
2016
34
Dual-Tracer PET/CT Using 18F-FDG and 11C-Acetate in Gastric Adenocarcinoma With Liver Metastasis. (27648704)
2016
35
Expression of podocalyxin-like protein is an independent prognostic biomarker in resected esophageal and gastric adenocarcinoma. (27478410)
2016
36
EXPRESSION OF E-CADHERIN AND WNT PATHWAY PROTEINS BETACATENIN, APC, TCF-4 AND SURVIVIN IN GASTRIC ADENOCARCINOMA: CLINICAL AND PATHOLOGICAL IMPLICATION. (28076475)
2016
37
The overexpression of MDM4: an effective and novel predictor of gastric adenocarcinoma lymph node metastasis. (27626496)
2016
38
Concurrent Gastric Adenocarcinoma of Fundic Gland Type and Carcinoma with Lymphoid Stroma: A Rare Case Report. (27462199)
2016
39
Gastric Adenocarcinoma: An Update on Genomics, Immune System Modulations, and Targeted Therapy. (27249691)
2016
40
Increased MACC1 expression indicates a poor prognosis independent of MET expression in gastric adenocarcinoma. (26719224)
2016
41
Decreased expression of BRCA1-associated protein 1 predicts unfavorable survival in gastric adenocarcinoma. (26611647)
2016
42
microRNA-25 Inhibits Cell Apoptosis of Human Gastric Adenocarcinoma Cell Line AGS via Regulating CCNE1 and MYC. (27120728)
2016
43
High Ki67 Expression has Prognostic Value in Surgically-Resected T3 Gastric Adenocarcinoma. (27012044)
2016
44
A Functional Polymorphism (rs2494752) in the AKT1 Promoter Region and Gastric Adenocarcinoma Risk in an Eastern Chinese Population. (26818920)
2016
45
The role of the obestatin/GPR39 system in human gastric adenocarcinomas. (26716511)
2016
46
DELAYED-ONSET BILATERAL DIFFUSE UVEAL MELANOCYTIC PROLIFERATION ASSOCIATED WITH GASTRIC ADENOCARCINOMA. (27662408)
2016
47
Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma. (27467911)
2016
48
Helicobacter pylori-negative early gastric adenocarcinoma with complete intestinal mucus phenotype mimicking verrucous gastritis. (27977882)
2016
49
The expression of metastasis-associated in colon cancer-1 and KAI1 in gastric adenocarcinoma and their clinical significance. (27793161)
2016
50
Gastric adenocarcinoma concurrent with paravertebral plasmacytoma: A case report. (27446469)
2016

Variations for Gastric Adenocarcinoma

About this section

Clinvar genetic disease variations for Gastric Adenocarcinoma:

5 (show all 72)
id Gene Variation Type Significance SNP ID Assembly Location
1TP53NM_ 000546.5(TP53): c.742C> T (p.Arg248Trp)SNVPathogenic/ Likely pathogenicrs121912651GRCh37Chr 17, 7577539: 7577539
2TP53NM_ 000546.5(TP53): c.733G> T (p.Gly245Cys)SNVPathogenic/ Likely pathogenicrs28934575GRCh37Chr 17, 7577548: 7577548
3TP53NM_ 000546.5(TP53): c.725G> A (p.Cys242Tyr)SNVPathogenic/ Likely pathogenicrs121912655GRCh37Chr 17, 7577556: 7577556
4TP53NM_ 000546.5(TP53): c.734G> A (p.Gly245Asp)SNVPathogenic/ Likely pathogenicrs121912656GRCh37Chr 17, 7577547: 7577547
5TP53NM_ 000546.5(TP53): c.743G> A (p.Arg248Gln)SNVPathogenic/ Likely pathogenicrs11540652GRCh37Chr 17, 7577538: 7577538
6TP53NM_ 000546.5(TP53): c.733G> A (p.Gly245Ser)SNVPathogenic/ Likely pathogenicrs28934575GRCh37Chr 17, 7577548: 7577548
7TP53NM_ 000546.5(TP53): c.818G> A (p.Arg273His)SNVPathogenic/ Likely pathogenicrs28934576GRCh37Chr 17, 7577120: 7577120
8TP53NM_ 000546.5(TP53): c.451C> A (p.Pro151Thr)SNVPathogenic/ Likely pathogenicrs28934874GRCh37Chr 17, 7578479: 7578479
9TP53NM_ 000546.5(TP53): c.451C> T (p.Pro151Ser)SNVPathogenic/ Likely pathogenicrs28934874GRCh37Chr 17, 7578479: 7578479
10HRASNM_ 005343.3(HRAS): c.34G> A (p.Gly12Ser)SNVPathogenic/ Likely pathogenicrs104894229GRCh37Chr 11, 534289: 534289
11HRASNM_ 005343.3(HRAS): c.35G> C (p.Gly12Ala)SNVPathogenic/ Likely pathogenicrs104894230GRCh37Chr 11, 534288: 534288
12HRASNM_ 005343.3(HRAS): c.37G> T (p.Gly13Cys)SNVPathogenic/ Likely pathogenicrs104894228GRCh37Chr 11, 534286: 534286
13HRASNM_ 005343.3(HRAS): c.436G> A (p.Ala146Thr)SNVPathogenic/ Likely pathogenicrs104894231GRCh37Chr 11, 533467: 533467
14HRASNM_ 005343.3(HRAS): c.437C> T (p.Ala146Val)SNVPathogenic/ Likely pathogenicrs121917759GRCh37Chr 11, 533466: 533466
15HRASNM_ 005343.3(HRAS): c.34G> T (p.Gly12Cys)SNVPathogenic/ Likely pathogenicrs104894229GRCh37Chr 11, 534289: 534289
16TP53NM_ 000546.5(TP53): c.535C> T (p.His179Tyr)SNVPathogenic/ Likely pathogenicrs587780070GRCh37Chr 17, 7578395: 7578395
17TP53NM_ 000546.5(TP53): c.659A> G (p.Tyr220Cys)SNVPathogenic/ Likely pathogenicrs121912666GRCh37Chr 17, 7578190: 7578190
18TP53NM_ 000546.5(TP53): c.701A> G (p.Tyr234Cys)SNVPathogenic/ Likely pathogenicrs587780073GRCh37Chr 17, 7577580: 7577580
19FGFR2NM_ 022970.3(FGFR2): c.755C> G (p.Ser252Trp)SNVPathogenic/ Likely pathogenicrs79184941GRCh37Chr 10, 123279677: 123279677
20TP53NM_ 000546.5(TP53): c.638G> A (p.Arg213Gln)SNVPathogenic/ Likely pathogenicrs587778720GRCh38Chr 17, 7674893: 7674893
21PIK3CANM_ 006218.3(PIK3CA): c.3140A> G (p.His1047Arg)SNVPathogenic/ Likely pathogenicrs121913279GRCh37Chr 3, 178952085: 178952085
22PIK3CANM_ 006218.3(PIK3CA): c.3140A> T (p.His1047Leu)SNVPathogenic/ Likely pathogenicrs121913279GRCh37Chr 3, 178952085: 178952085
23PIK3CANM_ 006218.3(PIK3CA): c.1633G> A (p.Glu545Lys)SNVPathogenic/ Likely pathogenicrs104886003GRCh37Chr 3, 178936091: 178936091
24PIK3CANM_ 006218.3(PIK3CA): c.1634A> G (p.Glu545Gly)SNVPathogenic/ Likely pathogenicrs121913274GRCh37Chr 3, 178936092: 178936092
25NRASNM_ 002524.4(NRAS): c.37G> C (p.Gly13Arg)SNVPathogenic/ Likely pathogenicrs121434595GRCh37Chr 1, 115258745: 115258745
26NRASNM_ 002524.4(NRAS): c.182A> G (p.Gln61Arg)SNVPathogenic/ Likely pathogenicrs11554290GRCh37Chr 1, 115256529: 115256529
27NRASNM_ 002524.4(NRAS): c.38G> A (p.Gly13Asp)SNVPathogenic/ Likely pathogenicrs121434596GRCh37Chr 1, 115258744: 115258744
28RAF1NM_ 002880.3(RAF1): c.770C> T (p.Ser257Leu)SNVPathogenic/ Likely pathogenicrs80338796GRCh37Chr 3, 12645699: 12645699
29BRAFNM_ 004333.4(BRAF): c.1801A> G (p.Lys601Glu)SNVPathogenic/ Likely pathogenicrs121913364GRCh37Chr 7, 140453134: 140453134
30AKT1NM_ 005163.2(AKT1): c.49G> A (p.Glu17Lys)SNVPathogenic/ Likely pathogenicrs121434592GRCh37Chr 14, 105246551: 105246551
31TP53NM_ 000546.5(TP53): c.844C> G (p.Arg282Gly)SNVPathogenic/ Likely pathogenicrs28934574GRCh37Chr 17, 7577094: 7577094
32TP53NM_ 000546.5(TP53): c.842A> G (p.Asp281Gly)SNVPathogenic/ Likely pathogenicrs587781525GRCh37Chr 17, 7577096: 7577096
33PIK3CANM_ 006218.3(PIK3CA): c.1634A> C (p.Glu545Ala)SNV, HaplotypePathogenic/ Likely pathogenicrs121913274GRCh37Chr 3, 178936092: 178936092
34CTNNB1NM_ 001904.3(CTNNB1): c.98C> A (p.Ser33Tyr)SNVPathogenic/ Likely pathogenicrs121913400GRCh37Chr 3, 41266101: 41266101
35CTNNB1NM_ 001904.3(CTNNB1): c.110C> G (p.Ser37Cys)SNVPathogenic/ Likely pathogenicrs121913403GRCh37Chr 3, 41266113: 41266113
36CTNNB1NM_ 001904.3(CTNNB1): c.98C> T (p.Ser33Phe)SNVPathogenic/ Likely pathogenicrs121913400GRCh37Chr 3, 41266101: 41266101
37CTNNB1NM_ 001904.3(CTNNB1): c.110C> T (p.Ser37Phe)SNVPathogenic/ Likely pathogenicrs121913403GRCh37Chr 3, 41266113: 41266113
38NRASNM_ 002524.4(NRAS): c.34G> A (p.Gly12Ser)SNVPathogenic/ Likely pathogenicrs121913250GRCh37Chr 1, 115258748: 115258748
39HRASNM_ 005343.3(HRAS): c.38G> T (p.Gly13Val)SNVPathogenic/ Likely pathogenicrs104894226GRCh38Chr 11, 534285: 534285
40TP53NM_ 000546.5(TP53): c.842A> T (p.Asp281Val)SNVPathogenic/ Likely pathogenicrs587781525GRCh38Chr 17, 7673778: 7673778
41TP53NM_ 000546.5(TP53): c.856G> A (p.Glu286Lys)SNVPathogenic/ Likely pathogenicrs786201059GRCh37Chr 17, 7577082: 7577082
42TP53NM_ 000546.5(TP53): c.584T> C (p.Ile195Thr)SNVPathogenic/ Likely pathogenicrs760043106GRCh38Chr 17, 7674947: 7674947
43PIK3CANM_ 006218.3(PIK3CA): c.1635G> T (p.Glu545Asp)SNVPathogenic/ Likely pathogenicrs121913275GRCh37Chr 3, 178936093: 178936093
44NRASNM_ 002524.4(NRAS): c.35G> C (p.Gly12Ala)SNVPathogenic/ Likely pathogenicrs121913237GRCh38Chr 1, 114716126: 114716126
45FGFR1NM_ 023110.2(FGFR1): c.1638C> A (p.Asn546Lys)SNVPathogenic/ Likely pathogenicrs779707422GRCh37Chr 8, 38274849: 38274849
46SMAD4NM_ 005359.5(SMAD4): c.1081C> G (p.Arg361Gly)SNVPathogenic/ Likely pathogenicrs80338963GRCh37Chr 18, 48591918: 48591918
47SMAD4NM_ 005359.5(SMAD4): c.1082G> A (p.Arg361His)SNVPathogenic/ Likely pathogenicrs377767347GRCh37Chr 18, 48591919: 48591919
48NRASNM_ 002524.4(NRAS): c.182A> C (p.Gln61Pro)SNVPathogenic/ Likely pathogenicrs11554290GRCh37Chr 1, 115256529: 115256529
49PIK3CANM_ 006218.3(PIK3CA): c.1624G> A (p.Glu542Lys)SNVPathogenic/ Likely pathogenicrs121913273GRCh37Chr 3, 178936082: 178936082
50HRASNM_ 005343.3(HRAS): c.37G> C (p.Gly13Arg)SNVPathogenic/ Likely pathogenicrs104894228GRCh37Chr 11, 534286: 534286
51NRASNM_ 002524.4(NRAS): c.183A> T (p.Gln61His)SNVPathogenic/ Likely pathogenicrs121913255GRCh37Chr 1, 115256528: 115256528
52NRASNM_ 002524.4(NRAS): c.182A> T (p.Gln61Leu)SNVPathogenic/ Likely pathogenicrs11554290GRCh37Chr 1, 115256529: 115256529
53NRASNM_ 002524.4(NRAS): c.38G> T (p.Gly13Val)SNVPathogenic/ Likely pathogenicrs121434596GRCh37Chr 1, 115258744: 115258744
54CTNNB1NM_ 001904.3(CTNNB1): c.110C> A (p.Ser37Tyr)SNVPathogenic/ Likely pathogenicrs121913403GRCh37Chr 3, 41266113: 41266113
55PIK3CANM_ 006218.3(PIK3CA): c.1633G> C (p.Glu545Gln)SNVPathogenic/ Likely pathogenicrs104886003GRCh37Chr 3, 178936091: 178936091
56KRASNM_ 004985.4(KRAS): c.351A> C (p.Lys117Asn)SNVPathogenic/ Likely pathogenicrs770248150GRCh37Chr 12, 25378647: 25378647
57ERBB2NM_ 004448.3(ERBB2): c.2305G> C (p.Asp769His)SNVPathogenic/ Likely pathogenicrs121913468GRCh38Chr 17, 39724008: 39724008
58ERBB2NM_ 001005862.2(ERBB2): c.2215G> T (p.Asp739Tyr)SNVPathogenic/ Likely pathogenicrs121913468GRCh37Chr 17, 37880261: 37880261
59ERBB2NM_ 004448.3(ERBB2): c.2524G> A (p.Val842Ile)SNVPathogenic/ Likely pathogenicrs1057519738GRCh37Chr 17, 37881332: 37881332
60TP53NM_ 000546.5(TP53): c.713G> T (p.Cys238Phe)SNVPathogenic/ Likely pathogenicrs730882005GRCh37Chr 17, 7577568: 7577568
61TP53NM_ 000546.5(TP53): c.523C> G (p.Arg175Gly)SNVPathogenic/ Likely pathogenicrs138729528GRCh37Chr 17, 7578407: 7578407
62NRASNM_ 002524.4(NRAS): c.35G> A (p.Gly12Asp)SNVPathogenic/ Likely pathogenicrs121913237GRCh37Chr 1, 115258747: 115258747
63PIK3CANM_ 006218.3(PIK3CA): c.3139C> T (p.His1047Tyr)SNVPathogenic/ Likely pathogenicrs121913281GRCh37Chr 3, 178952084: 178952084
64NRASNM_ 002524.4(NRAS): c.34G> T (p.Gly12Cys)SNVPathogenic/ Likely pathogenicrs121913250GRCh37Chr 1, 115258748: 115258748
65NRASNM_ 002524.4(NRAS): c.34G> C (p.Gly12Arg)SNVPathogenic/ Likely pathogenicrs121913250GRCh37Chr 1, 115258748: 115258748
66NRASNM_ 002524.4(NRAS): c.35G> T (p.Gly12Val)SNVPathogenic/ Likely pathogenicrs121913237GRCh37Chr 1, 115258747: 115258747
67BRAFNM_ 004333.4(BRAF): c.1802A> C (p.Lys601Thr)SNVPathogenic/ Likely pathogenicrs397507484GRCh37Chr 7, 140453133: 140453133
68KRASNM_ 033360.3(KRAS): c.183A> T (p.Gln61His)SNVPathogenic/ Likely pathogenicrs17851045GRCh37Chr 12, 25380275: 25380275
69NRASNM_ 002524.4(NRAS): c.181C> A (p.Gln61Lys)SNVPathogenic/ Likely pathogenicrs121913254GRCh37Chr 1, 115256530: 115256530
70PTENNM_ 000314.6(PTEN): c.389G> A (p.Arg130Gln)SNVPathogenic/ Likely pathogenicrs121909229GRCh37Chr 10, 89692905: 89692905
71SMAD4NM_ 005359.5(SMAD4): c.1081C> T (p.Arg361Cys)SNVPathogenic/ Likely pathogenicrs80338963GRCh37Chr 18, 48591918: 48591918
72SMAD4NM_ 005359.5(SMAD4): c.1157G> A (p.Gly386Asp)SNVPathogenic/ Likely pathogenicrs121912580GRCh37Chr 18, 48593406: 48593406

Copy number variations for Gastric Adenocarcinoma from CNVD:

6 (show all 39)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1149631111600000115900000GainC1orf88Gastric adenocarcinoma
2149641111600000115900000GainCHIAGastric adenocarcinoma
3149661111600000115900000GainOVGP1Gastric adenocarcinoma
43399215130000056200000LossLRP8Gastric adenocarcinoma
5381601013000000GainDIP2CGastric adenocarcinoma
6482241099400000102000000GainCHUKGastric adenocarcinoma
7482251099400000102000000GainCWF19L1Gastric adenocarcinoma
8482261099400000102000000GainSPFH1Gastric adenocarcinoma
94832311121600000GainST5Gastric adenocarcinoma
1066124122535817925403863AmplificationKRASGastric adenocarcinoma
1180193138650000088800000LossSLITRK5Gastric adenocarcinoma
128149714103000000106368585LossIGHV3-22Gastric adenocarcinoma
1392520154140000042700000LossCAPN3Gastric adenocarcinoma
1492521154140000042700000LossGANCGastric adenocarcinoma
1593577155580000057100000GainLDHAL6BGastric adenocarcinoma
1693578155580000057100000GainMYO1EGastric adenocarcinoma
1797919161470000016700000GainPKD1P3Gastric adenocarcinoma
181120231737739173814485LossATP2A3Gastric adenocarcinoma
19112078173784439237884914AmplificationGastric adenocarcinoma
201123101738544873993002LossZZEF1Gastric adenocarcinoma
21130603195000000053800000GainGastric adenocarcinoma
2213599112128122223128954165GainTMEM132DGastric adenocarcinoma
23159208214140000046944323LossHSF2BPGastric adenocarcinoma
24159209214140000046944323LossKIAA0179Gastric adenocarcinoma
25166094313500000LossCNTN6Gastric adenocarcinoma
2616982731470000023800000LossUBE2E1Gastric adenocarcinoma
271823134139500000141700000LossMAML3Gastric adenocarcinoma
281842564172200000176600000LossGastric adenocarcinoma
291955915152100000155600000LossTIMD4Gastric adenocarcinoma
3020133156840000073300000GainFCHO2Gastric adenocarcinoma
312212977142800000147500000LossCNTNAP2Gastric adenocarcinoma
3223370781270000019100000GainGastric adenocarcinoma
3323693881910000023400000LossINTS10Gastric adenocarcinoma
3423747782340000027400000LossCDCA2Gastric adenocarcinoma
3523747882340000027400000LossDOCK5Gastric adenocarcinoma
3623747982340000027400000LossGNRH1Gastric adenocarcinoma
3723748082340000027400000LossKCTD9Gastric adenocarcinoma
3823788382740000029700000LossEXTL3Gastric adenocarcinoma
39262032X2940000031500000GainXKGastric adenocarcinoma

Expression for genes affiliated with Gastric Adenocarcinoma

About this section
Search GEO for disease gene expression data for Gastric Adenocarcinoma.

Pathways for genes affiliated with Gastric Adenocarcinoma

About this section

GO Terms for genes affiliated with Gastric Adenocarcinoma

About this section

Cellular components related to Gastric Adenocarcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1apical junction complexGO:004329610.7CDH1, CTNNB1
2catenin complexGO:001634210.6CDH1, CTNNB1
3flotillin complexGO:001660010.6CDH1, CTNNB1
4lateral plasma membraneGO:00163289.9CDH1, CLDN4, CTNNB1

Biological processes related to Gastric Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 7)
idNameGO IDScoreTop Affiliating Genes
1cellular response to indole-3-methanolGO:007168110.8CDH1, CTNNB1
2entry of bacterium into host cellGO:003563510.8CDH1, CTNNB1
3ovulationGO:003072810.8MYC, PTGS2
4digestionGO:000758610.4CCKBR, CTSE, TFF1
5cell proliferationGO:000828310.3CCKBR, CTNNB1, ERBB2, MYC, ROS1
6positive regulation of cell proliferationGO:000828410.1CCKBR, CDX2, CTNNB1, MYC, PTGS2
7wound healingGO:00420609.9ERBB2, S100A8, TFF1

Molecular functions related to Gastric Adenocarcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1protein phosphatase bindingGO:001990310.0CTNNB1, ERBB2, ROS1

Sources for Gastric Adenocarcinoma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet